WO2012109025A3 - Diagnostic de cancer du sein à l'aide d'une décharge de mamelon - Google Patents

Diagnostic de cancer du sein à l'aide d'une décharge de mamelon Download PDF

Info

Publication number
WO2012109025A3
WO2012109025A3 PCT/US2012/022754 US2012022754W WO2012109025A3 WO 2012109025 A3 WO2012109025 A3 WO 2012109025A3 US 2012022754 W US2012022754 W US 2012022754W WO 2012109025 A3 WO2012109025 A3 WO 2012109025A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
nipple
discharge
nipple discharge
panel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/022754
Other languages
English (en)
Other versions
WO2012109025A2 (fr
Inventor
Edward R. Sauter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Dakota UND
Original Assignee
University of North Dakota UND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Dakota UND filed Critical University of North Dakota UND
Priority to US13/984,217 priority Critical patent/US20140038211A1/en
Priority to EP12745305.8A priority patent/EP2673645A4/fr
Priority to CN201280008382.1A priority patent/CN103842822A/zh
Publication of WO2012109025A2 publication Critical patent/WO2012109025A2/fr
Anticipated expiration legal-status Critical
Publication of WO2012109025A3 publication Critical patent/WO2012109025A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un panel de marqueurs biologiques pour la prédiction d'un cancer du sein à l'aide d'une décharge de mamelon, ainsi que sur un procédé et des trousses pour utiliser ceux-ci. Une décharge de mamelon peut être une décharge de fluide ou une décharge spontanée par aspiration du mamelon. Le panel a été sélectionné pour optimiser la capacité de prédiction tout en réduisant au minimum le nombre de marqueurs à dépister. Tel qu'observé, le panel s'approche d'une précision à cent pour cent pour prédire un cancer du sein sans avoir besoin d'une biopsie invasive.
PCT/US2012/022754 2011-02-10 2012-01-26 Diagnostic de cancer du sein à l'aide d'une décharge de mamelon Ceased WO2012109025A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/984,217 US20140038211A1 (en) 2011-02-10 2012-01-26 Breast cancer diagnosis using nipple discharge
EP12745305.8A EP2673645A4 (fr) 2011-02-10 2012-01-26 Diagnostic de cancer du sein à l'aide d'une décharge de mamelon
CN201280008382.1A CN103842822A (zh) 2011-02-10 2012-01-26 使用乳头溢液的乳癌诊断

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441452P 2011-02-10 2011-02-10
US61/441,452 2011-02-10

Publications (2)

Publication Number Publication Date
WO2012109025A2 WO2012109025A2 (fr) 2012-08-16
WO2012109025A3 true WO2012109025A3 (fr) 2014-04-10

Family

ID=46639127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022754 Ceased WO2012109025A2 (fr) 2011-02-10 2012-01-26 Diagnostic de cancer du sein à l'aide d'une décharge de mamelon

Country Status (4)

Country Link
US (1) US20140038211A1 (fr)
EP (1) EP2673645A4 (fr)
CN (1) CN103842822A (fr)
WO (1) WO2012109025A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128830A1 (en) * 2015-04-16 2018-05-10 Juliet V. Spencer Detection of human cytomegalovirus in breast cancer
CN113930498A (zh) * 2020-06-29 2022-01-14 浙江省肿瘤医院 一种检测乳头溢液中rasef基因表达的方法及其乳腺癌筛查试剂盒
CN114814224A (zh) * 2021-09-30 2022-07-29 山东大学齐鲁医院 乳头溢液中的Hsp90α在乳腺癌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211624A1 (en) * 2001-11-20 2003-11-13 Board Of Regents, The University Of Texas System Proteomic methods for diagnosis and monitoring of breast cancer
US20060252097A1 (en) * 2005-05-02 2006-11-09 The Curators Of The University Of Missouri Detection of carbohydrate biomarkers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA119095A (fr) 1909-05-25 1909-06-22 Arthur L. Piper Poele
US20090087860A1 (en) * 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
EP2065399A1 (fr) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH La présente invention concerne des méthodes de prédiction du succès thérapeutique d'une thérapie anti cancer du sein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211624A1 (en) * 2001-11-20 2003-11-13 Board Of Regents, The University Of Texas System Proteomic methods for diagnosis and monitoring of breast cancer
US20060252097A1 (en) * 2005-05-02 2006-11-09 The Curators Of The University Of Missouri Detection of carbohydrate biomarkers

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"AMA Code of Medical Ethics", OPINION 9.095-REPORTING CLINICAL TEST RESULTS: GENERAL GUIDELINES., December 1998 (1998-12-01), XP008171746, Retrieved from the Internet <URL:http://www.ama-assn.org/ama/pub/physician-resources/medical-ethicslcode-medical-ethics/opinion8095.page?> [retrieved on 20120518] *
"IMUBIND Tissue PAI-1 ELISA Kit", PRODUCT NO. 821., 13 March 2009 (2009-03-13), pages 3, XP055136652 *
DEUTSCHER, S. ET AL.: "Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.", BMC CANCER, vol. 10, 2010, pages 519 - 526, XP021075341 *
QIN, W. ET AL.: "Nipple Aspirate Fluid Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Inihibitor-1, and Urokinase-Type Plasminogen Activator Receptor Predicts Breast Cancer Diagnosis and Advanced Disease.", ANNALS OF SURGICAL ONCOLOGY, vol. 10, 2003, pages 948 - 953, XP019369362 *
QIN, W. ET AL.: "Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.", BMC CANCER, vol. 12, 2012, pages 52 - 58, XP021123543 *
TOKUDA, Y. ET AL.: "Suspicious Nipple Discharge Diagnostic Evaluation. Imaging of the Breast--Technical Aspects and Clinical Implication", INTECH OPEN ACCESS PUBLISHER, 16 March 2012 (2012-03-16), pages 19, XP055136650, Retrieved from the Internet <URL:hftp://www.intechopen.com/statistics/32013> [retrieved on 20120517] *
ZERVOUDIS, S. ET AL.: "Nipple Discharge Screening. Medscape Education", WOMEN'S HEALTH., 16 December 2009 (2009-12-16), pages 23, XP055136645, Retrieved from the Internet <URL:http://www.medscape.orglviewarticle/713539> [retrieved on 20120517] *

Also Published As

Publication number Publication date
EP2673645A2 (fr) 2013-12-18
WO2012109025A2 (fr) 2012-08-16
EP2673645A4 (fr) 2015-02-25
CN103842822A (zh) 2014-06-04
US20140038211A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
WO2012047618A3 (fr) Biomarqueurs de mésothéliome et utilisations de ceux-ci
WO2013087887A3 (fr) Biomarqueurs et paramètres pour troubles hypertensifs de grossesse
WO2012076553A3 (fr) Biomarqueurs et paramètres des troubles d&#39;hypertension de la grossesse
WO2011128357A3 (fr) Biomarqueurs de troubles liés à l&#39;hypertension pendant la grossesse
WO2009037572A3 (fr) Combinaisons de bio-marqueurs du cancer colorectal
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l&#39;hôte
WO2012021795A3 (fr) Biomarqueurs du cancer du pancréas et leurs utilisations
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
WO2010135692A3 (fr) Biomarqueurs miarn d&#39;une maladie prostatique
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
HK1246828A1 (zh) 用於检测癌症的生物标志物组
HK1223361A1 (zh) 用於预测肠易激综合征诊断的途径特异性测定
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EP3054299A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
MX2009011007A (es) Biomarcadores para esclerosis multiple.
WO2011112845A3 (fr) Méthodes et compositions associés à un essai de méthylation multiple pour prédire l&#39;évolution de l&#39;état de santé d&#39;un patient
WO2013057581A8 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
HK1220253A1 (zh) 诊断前列腺癌症的方法
WO2013028807A3 (fr) Biomarqueurs du carcinome cellulaire rénal et leurs utilisations
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
WO2012135749A3 (fr) Marqueurs biologiques pour prévoir la sensibilité à des traitements du cancer
WO2013079981A3 (fr) Procédés basés sur des marqueurs biologiques et biopuces pour aider au diagnostic d&#39;un accident vasculaire cérébral
AU2012339149A8 (en) Method for the diagnosis of Niemann-Pick disease
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013062261A3 (fr) Marqueur récemment identifié du cancer du côlon et trousse de diagnostic l&#39;utilisant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12745305

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012745305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13984217

Country of ref document: US